


PROGRESSIVE'S EVENING STROLL

DATE: 17 September, 2026

Market Snapshot:

The follow-through move pushed the Index higher after a steady start, but it immediately wiped out all its gains in the opening trade. Support from Pharma, Auto and other heavyweights lifted the Index higher. However, the Index gave up some of its gains towards the close and eventually settled at 23,270.60, up by 53 points. Except for the two Banking Indices, all sectors ended in positive territory, with Pharma and Defence emerging as the top performers. In the broader markets, Midcaps and Smallcaps soared by 0.92% and 0.76%, respectively, outperforming the Frontline Index.

HOW THE DAY TRENDED



INDICES			
Index	Close	Points	%Chg.
Sensex	74314.59	(21.86)	(0.03)
Nifty50	23270.60	53.00	0.23
Nifty Midcap 100	61432.10	557.90	0.92
Nifty Small Cap 100	19535.70	147.40	0.76

SECTORAL GAINERS / LOSERS			
Sectors	Close	Points	%Chg.
NIFTY PHARMA	26579.25	433.05	1.66
NIFTY DEFENCE	9271.90	142.80	1.56
NIFTY PSU BANK	8262.80	(13.10)	(0.16)
NIFTY BANK	56055.75	(236.70)	(0.42)

NIFTY TOP GAINERS / LOSERS					
Gainers	CMP (Rs)	%Chg.	Losers	CMP (Rs)	%Chg.
HDFC LIFE	557.00	5.05	ONGC	232.43	(1.85)
TMPV	314.50	4.49	TITAN	4841.00	(1.38)
SBI LIFE	1766.90	4.06	HDFC BANK	713.00	(1.18)
DR REDDY	1175.00	3.07	COAL INDIA	418.00	(1.01)

INDICES LEVELS FOR September 18, 2026

Nifty (future)	
Resistance	23500
Support	23250

Bank Nifty (future)	
Resistance	56900
Support	56000



KEY TAKEAWAYS OF THE DAY

◆ **Fortis Healthcare moves Supreme Court against Delhi HC forensic audit order; Axis Bank may follow:**

In a significant legal move, Fortis Healthcare has appealed to the Supreme Court against a Delhi High Court decision requiring a forensic audit of its dealings with IHH Healthcare. This case is part of larger litigation concerning Daiichi Sankyo Company. IHH Healthcare, based in Malaysia, maintains a controlling interest in Fortis. Notably, Axis Bank is also gearing up to challenge the High Court's ruling. Furthermore, the company has signed definitive agreements with Seth Sunder Lal Jain Charitable Eye Hospital to provide healthcare services at a 400+ bed super-specialty hospital in Ashok Vihar, New Delhi. The hospital is expected to commence operations in three to four years.

◆ **Infosys expands Indore facility with new software block:**

The company announced the expansion of its Indore Development Center (DC) to further strengthen its presence in Central India. The expanded infrastructure will bolster the company's capabilities in artificial intelligence (AI), machine learning, cloud services, application development, and cybersecurity to address evolving customer needs.

◆ **Alembic Pharma gets USFDA inspection closure for Vadodara bioequivalence facility:**

The USFDA has issued an Establishment Inspection Report (EIR) and closed the inspection of Alembic Pharmaceuticals' bioequivalence facility in Vadodara, Gujarat. The USFDA conducted the inspection from March 3 to March 7, 2025.

◆ **Maharashtra signs Rs27,000cr MoU with Mazagon Dock For 2 million gross tonnage shipbuilding hub:**

Mazagon Dock has signed an MoU with National Shipbuilding and Heavy Industries Park Maharashtra Ltd (NShipML) to develop a major shipbuilding facility at Dighi in Raigad district. The proposed project is expected to involve an investment of around Rs27,000cr and enable the construction of large commercial vessels.

◆ **G R Infraprojects terminates NTPC BESS EPC contracts:**

G R Infraprojects has abruptly terminated its engineering, procurement, and construction (EPC) contract with NTPC for a battery energy storage project at the Mouda Super Thermal Power Station in Maharashtra. The company cited persistent force majeure events, war risk circumstances, and contractual issues as reasons, subsequently triggering a dispute resolution process to protect its rights. The terminated EPC contract for the BESS implementation at NTPC's Mouda Super Thermal Power Station in Maharashtra was valued at Rs413.37cr, excluding GST.

Source: Media Reports



DISCLAIMERS AND DISCLOSURES-

Progressive Share Brokers Pvt. Ltd. and its affiliates are a full-service, brokerage and financing group. Progressive Share Brokers Pvt. Ltd. (PSBPL) along with its affiliates are participants in virtually all securities trading markets in India. PSBPL started its operation on the National Stock Exchange (NSE) in 1996. PSBPL is a corporate trading member of Bombay Stock Exchange Limited (BSE), National Stock Exchange of India Limited (NSE) for its stock broking services and is Depository Participant with Central Depository Services Limited (CDSL) and is a member of Association of Mutual Funds of India (AMFI) for distribution of financial products.

PSBPL is SEBI registered Research Analyst under SEBI (Research Analysts) Regulations, 2014 with SEBI Registration No. INH000000859/Research Analyst BSE Enlistment No. 5049. PSBPL hereby declares that it has not defaulted with any stock exchange nor its activities were suspended by any stock exchange with whom it is registered in last five years. PSBPL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

PSBPL offers research services to clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Other disclosures by Progressive Share Brokers Pvt. Ltd. (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company (s) covered in this report:-

- PSBPL or its associates financial interest in the subject company: NO
- Research Analyst (s) or his/her relative's financial interest in the subject company: NO
- PSBPL or its associates and Research Analyst or his/her relative's does not have any material conflict of interest in the subject company. The research Analyst or research entity (PSBPL) has not been engaged in market making activity for the subject company.
- PSBPL or its associates actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report: NO
- Research Analyst or his/her relatives have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report: NO
- PSBPL or its associates may have received any compensation including for brokerage services from the subject company in the past 12 months. PSBPL or its associates may have received compensation for products or services other than brokerage services from the subject company in the past 12 months. PSBPL or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report. Subject Company may have been client of PSBPL or its associates during twelve months preceding the date of distribution of the research report and PSBPL may have co-managed public offering of securities for the subject company in the past twelve months.
- The research analyst has served as officer, director or employee of the subject company: NO
- Registration granted by SEBI and certification from NISM is in no way guarantee performance of the intermediary or provide any assurance of returns to investors

PSBPL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. Our sales people, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses (if any) may make investment decisions that may be inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution publication, availability or use would be contrary to law or regulation or which would subject PSBPL or its group companies to any registration or licensing requirement within such jurisdiction. If this document is sent or has reached any individual in such country, especially, USA, the same may be ignored. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of PSBPL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of PSBPL or its Group Companies. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

Terms & Conditions:

This report has been prepared by PSBPL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of PSBPL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and its at discretion of the clients to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. PSBPL will not treat recipients as customers by virtue of their receiving this report.

Registered Office Address:

Progressive Share Brokers Pvt. Ltd,
122-124, Laxmi Plaza, Laxmi Indl Estate,
New Link Rd, Andheri West,
Mumbai—400053, Maharashtra
www.progressiveshares.com | Contact No.:022-40777500.

Compliance Officer:

Ms. Mamatha Poojari,
Email: compliance@progressiveshares.com,
Contact No.:022-40777500.

Grievance Officer:

Email: grievancecell@progressiveshares.com

